Unichem Laboratories Limited
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical in… Read more
Unichem Laboratories Limited (UNICHEMLAB) - Net Assets
Latest net assets as of September 2025: ₹24.35 Billion INR
Based on the latest financial reports, Unichem Laboratories Limited (UNICHEMLAB) has net assets worth ₹24.35 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹35.56 Billion) and total liabilities (₹11.21 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹24.35 Billion |
| % of Total Assets | 68.47% |
| Annual Growth Rate | 12.43% |
| 5-Year Change | -4.16% |
| 10-Year Change | 156.65% |
| Growth Volatility | 33.28 |
Unichem Laboratories Limited - Net Assets Trend (2005–2025)
This chart illustrates how Unichem Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Unichem Laboratories Limited (2005–2025)
The table below shows the annual net assets of Unichem Laboratories Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹24.51 Billion | +3.73% |
| 2024-03-31 | ₹23.62 Billion | -2.99% |
| 2023-03-31 | ₹24.35 Billion | -6.99% |
| 2022-03-31 | ₹26.18 Billion | +2.41% |
| 2021-03-31 | ₹25.57 Billion | +1.01% |
| 2020-03-31 | ₹25.31 Billion | -3.38% |
| 2019-03-31 | ₹26.20 Billion | -2.25% |
| 2018-03-31 | ₹26.80 Billion | +151.98% |
| 2017-03-31 | ₹10.64 Billion | +11.39% |
| 2016-03-31 | ₹9.55 Billion | +10.06% |
| 2015-03-31 | ₹8.68 Billion | +6.23% |
| 2014-03-31 | ₹8.17 Billion | +12.31% |
| 2013-03-31 | ₹7.27 Billion | +10.07% |
| 2012-03-31 | ₹6.61 Billion | +6.94% |
| 2011-03-31 | ₹6.18 Billion | +9.73% |
| 2010-03-31 | ₹5.63 Billion | +16.20% |
| 2009-03-31 | ₹4.84 Billion | +17.72% |
| 2008-03-31 | ₹4.12 Billion | +2.27% |
| 2007-03-31 | ₹4.02 Billion | +15.91% |
| 2006-03-31 | ₹3.47 Billion | +47.46% |
| 2005-03-31 | ₹2.35 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Unichem Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2456180000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹24.56 Billion | 100.23% |
| Common Stock | ₹140.80 Million | 0.57% |
| Other Comprehensive Income | ₹-210.00 Million | -0.86% |
| Other Components | ₹13.30 Million | 0.05% |
| Total Equity | ₹24.51 Billion | 100.00% |
Unichem Laboratories Limited Competitors by Market Cap
The table below lists competitors of Unichem Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chaowei Power Holdings Limited
STU:EWC
|
$72.55 Million |
|
Vimta Labs Limited
NSE:VIMTALABS
|
$72.56 Million |
|
SPML Infra Limited
NSE:SPMLINFRA
|
$72.56 Million |
|
Jeffersonville Bancorp
OTCQB:JFBC
|
$72.57 Million |
|
Genasys Inc
NASDAQ:GNSS
|
$72.51 Million |
|
Elanders AB Series B
LSE:0JBY
|
$72.49 Million |
|
MSP Steel & Power Limited
NSE:MSPL
|
$72.46 Million |
|
DT Cloud Star Acquisition Corporation Units
NASDAQ:DTSQU
|
$72.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Unichem Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,624,188,000 to 24,505,900,000, a change of 881,712,000 (3.7%).
- Net income of 1,375,200,000 contributed positively to equity growth.
- Dividend payments of 3,400,000 reduced retained earnings.
- Other comprehensive income decreased equity by 289,310,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹1.38 Billion | +5.61% |
| Dividends Paid | ₹3.40 Million | -0.01% |
| Other Comprehensive Income | ₹-289.31 Million | -1.18% |
| Other Changes | ₹-200.78 Million | -0.82% |
| Total Change | ₹- | 3.73% |
Book Value vs Market Value Analysis
This analysis compares Unichem Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 12.57x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹24.90 | ₹313.10 | x |
| 2006-03-31 | ₹46.28 | ₹313.10 | x |
| 2007-03-31 | ₹57.17 | ₹313.10 | x |
| 2008-03-31 | ₹58.46 | ₹313.10 | x |
| 2009-03-31 | ₹68.82 | ₹313.10 | x |
| 2010-03-31 | ₹79.97 | ₹313.10 | x |
| 2011-03-31 | ₹87.75 | ₹313.10 | x |
| 2012-03-31 | ₹93.84 | ₹313.10 | x |
| 2013-03-31 | ₹103.29 | ₹313.10 | x |
| 2014-03-31 | ₹116.01 | ₹313.10 | x |
| 2015-03-31 | ₹123.24 | ₹313.10 | x |
| 2016-03-31 | ₹135.65 | ₹313.10 | x |
| 2017-03-31 | ₹151.10 | ₹313.10 | x |
| 2018-03-31 | ₹380.74 | ₹313.10 | x |
| 2019-03-31 | ₹372.19 | ₹313.10 | x |
| 2020-03-31 | ₹359.61 | ₹313.10 | x |
| 2021-03-31 | ₹363.23 | ₹313.10 | x |
| 2022-03-31 | ₹371.98 | ₹313.10 | x |
| 2023-03-31 | ₹345.97 | ₹313.10 | x |
| 2024-03-31 | ₹335.55 | ₹313.10 | x |
| 2025-03-31 | ₹346.95 | ₹313.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Unichem Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.61%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.51%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.46x
- Recent ROE (5.61%) is below the historical average (15.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 39.09% | 14.32% | 1.32x | 2.07x | ₹618.50 Million |
| 2006 | 24.65% | 14.67% | 1.07x | 1.56x | ₹477.25 Million |
| 2007 | 17.46% | 11.19% | 1.06x | 1.48x | ₹300.10 Million |
| 2008 | 12.36% | 7.58% | 1.11x | 1.47x | ₹97.31 Million |
| 2009 | 22.33% | 14.71% | 1.05x | 1.45x | ₹597.11 Million |
| 2010 | 21.82% | 16.43% | 0.93x | 1.42x | ₹665.14 Million |
| 2011 | 15.41% | 11.55% | 0.94x | 1.43x | ₹334.25 Million |
| 2012 | 10.79% | 8.14% | 0.89x | 1.49x | ₹51.99 Million |
| 2013 | 15.57% | 10.48% | 1.01x | 1.48x | ₹405.19 Million |
| 2014 | 20.73% | 14.94% | 0.99x | 1.40x | ₹876.47 Million |
| 2015 | 8.69% | 6.27% | 1.03x | 1.35x | ₹-113.62 Million |
| 2016 | 11.31% | 8.10% | 1.04x | 1.35x | ₹125.51 Million |
| 2017 | 10.22% | 7.15% | 1.00x | 1.43x | ₹23.13 Million |
| 2018 | 94.96% | 327.05% | 0.24x | 1.19x | ₹22.77 Billion |
| 2019 | -0.91% | -2.12% | 0.36x | 1.20x | ₹-2.86 Billion |
| 2020 | -2.38% | -5.20% | 0.37x | 1.24x | ₹-3.13 Billion |
| 2021 | 1.34% | 2.85% | 0.39x | 1.22x | ₹-2.21 Billion |
| 2022 | 1.26% | 2.63% | 0.38x | 1.27x | ₹-2.29 Billion |
| 2023 | -8.30% | -15.26% | 0.42x | 1.31x | ₹-4.46 Billion |
| 2024 | -2.98% | -4.25% | 0.52x | 1.34x | ₹-3.07 Billion |
| 2025 | 5.61% | 6.51% | 0.59x | 1.46x | ₹-1.08 Billion |
Industry Comparison
This section compares Unichem Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Unichem Laboratories Limited (UNICHEMLAB) | ₹24.35 Billion | 39.09% | 0.46x | $72.52 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |